JP2007508397A - 前立腺癌の治療方法およびその治療組成物 - Google Patents
前立腺癌の治療方法およびその治療組成物 Download PDFInfo
- Publication number
- JP2007508397A JP2007508397A JP2006536528A JP2006536528A JP2007508397A JP 2007508397 A JP2007508397 A JP 2007508397A JP 2006536528 A JP2006536528 A JP 2006536528A JP 2006536528 A JP2006536528 A JP 2006536528A JP 2007508397 A JP2007508397 A JP 2007508397A
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- estrogen receptor
- prostate cancer
- receptor modulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
本発明は、初期および後期段階の前立腺癌患者に対するアジュバント療法の安全且つ有効な提供方法を提供する。過去に、アジュバント療法は、癌の転移性によって示される前立腺癌が進行した患者のみに利用可能であったが、本発明は、前立腺癌および他の癌の治療で使用されている2つの薬物クラスの組合わせ療法により前立腺癌をより抑制することができ、且つ前立腺癌の全形態のためのより有効な初期治療を得ることができることを見出した。より詳細には、本発明は、非ステロイド系アンドロゲン薬と選択的エストロゲン受容体モジュレーター化合物との組み合わせによりいずれかの薬物が個別に摂取されるより良好な結果が得られることを見出した。
Claims (16)
- 単位投薬形態で治療有効量の非ステロイド系抗アンドロゲン薬またはその薬学的に許容可能な塩および非ステロイド系抗アンドロゲン薬を増強するための治療有効量の選択的エストロゲン受容体モジュレーターまたはその薬学的に許容可能な塩を含む、治療を必要とする患者の前立腺癌の治療に適合させた薬学的組成物。
- 前記組成物が、約40〜約200mgの前記非ステロイド系抗アンドロゲン薬またはその薬学的に許容可能な塩および約10〜約80mgの前記選択的エストロゲン受容体モジュレーターまたはその薬学的に許容可能な塩を含む、請求項1に記載の組成物。
- 前記非ステロイド系抗アンドロゲン薬が、ビカルタミド、フルタミド、ニルタミド、およびその混合物からなる群から選択される、請求項1に記載の組成物。
- 前記選択的エストロゲン受容体モジュレーターが、タモキシフェン、ラロキシフェン、トレミフェン、およびその混合物からなる群から選択される、請求項1に記載の組成物。
- 前記非ステロイド系抗アンドロゲン薬が、ビカルタミドまたはその薬学的に許容可能な塩である、請求項1に記載の組成物。
- 前記選択的エストロゲン受容体モジュレーターが、タモキシフェンまたはその薬学的に許容可能な塩である、請求項1に記載の組成物。
- 前記選択的エストロゲン受容体モジュレーターが、ラロキシフェンまたはその薬学的に許容可能な塩である、請求項1に記載の組成物。
- 治療有効量の非ステロイド系抗アンドロゲン薬またはその薬学的に許容可能な塩と非ステロイド系抗アンドロゲン薬増強アジュバントとの組み合わせを投与する工程を含み、前記アジュバントは本質的に非ステロイド系抗アンドロゲン薬増強量の選択的エストロゲン受容体モジュレーターまたはその薬学的に許容可能な塩からなる、治療を必要とする患者の前立腺癌の治療方法。
- 前記組み合わせが、約40〜約200mgの前記非ステロイド系抗アンドロゲン薬またはその薬学的に許容可能な塩および約10〜約80mgの前記選択的エストロゲン受容体モジュレーターまたはその薬学的に許容可能な塩を含む、請求項8に記載の方法。
- 前記組み合わせを単位投薬形態で投与する、請求項8に記載の方法。
- 前記組み合わせを異なる投薬形態で同時に投与する、請求項8に記載の方法。
- 前記非ステロイド系抗アンドロゲン薬が、ビカルタミド、フルタミド、ニルタミド、およびその混合物からなる群から選択される、請求項8に記載の方法。
- 前記選択的エストロゲン受容体モジュレーターが、タモキシフェン、ラロキシフェン、トレミフェン、およびその混合物からなる群から選択される、請求項8に記載の方法。
- 前記非ステロイド系抗アンドロゲン薬が、ビカルタミドまたはその薬学的に許容可能な塩である、請求項8に記載の方法。
- 前記選択的エストロゲン受容体モジュレーターが、タモキシフェンまたはその薬学的に許容可能な塩である、請求項8に記載の方法。
- 前記選択的エストロゲン受容体モジュレーターが、ラロキシフェンまたはその薬学的に許容可能な塩である、請求項8に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44093703P | 2003-01-17 | 2003-01-17 | |
US10/754,308 US7332525B2 (en) | 2003-01-17 | 2004-01-09 | Method of treatment of prostate cancer and composition for treatment thereof |
PCT/US2004/000668 WO2004066962A2 (en) | 2003-01-17 | 2004-01-12 | Method of treatment of prostate cancer and composition for treatment thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007508397A true JP2007508397A (ja) | 2007-04-05 |
JP2007508397A5 JP2007508397A5 (ja) | 2011-05-26 |
Family
ID=32718199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006536528A Pending JP2007508397A (ja) | 2003-01-17 | 2004-01-12 | 前立腺癌の治療方法およびその治療組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7332525B2 (ja) |
EP (1) | EP1583536B1 (ja) |
JP (1) | JP2007508397A (ja) |
KR (1) | KR20050096135A (ja) |
AU (1) | AU2004207442B2 (ja) |
CA (1) | CA2509390C (ja) |
MX (1) | MXPA05007583A (ja) |
WO (1) | WO2004066962A2 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
US20040214898A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S. | Methods for treating hot flashes |
US20040213841A1 (en) * | 2001-11-29 | 2004-10-28 | Steiner Mitchell S | Methods for treating hot flashes and gynecomastia |
US20050080143A1 (en) * | 2001-11-29 | 2005-04-14 | Steiner Mitchell S. | Treatment of androgen-deprivation induced osteoporosis |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20040096510A1 (en) * | 2001-11-29 | 2004-05-20 | Steiner Mitchell S. | Prevention and treatment of androgen-deprivation induced osteoporosis |
US7524866B2 (en) * | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
US20080027010A1 (en) * | 2004-09-02 | 2008-01-31 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using Na+/K+-ATPase inhibitors |
EP1789090A2 (en) * | 2004-09-02 | 2007-05-30 | Bionaut Pharmaceuticals, Inc. | Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors |
ATE509630T1 (de) * | 2004-09-02 | 2011-06-15 | Bionaut Pharmaceuticals Inc | Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern |
US20060135468A1 (en) | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Treatment of refractory cancers using NA+/K+ ATPase inhibitors |
US20070105790A1 (en) * | 2004-09-02 | 2007-05-10 | Bionaut Pharmaceuticals, Inc. | Pancreatic cancer treatment using Na+/K+ ATPase inhibitors |
WO2006044916A2 (en) * | 2004-10-18 | 2006-04-27 | Bionaut Pharmaceuticals, Inc. | Use of na+/ k+-atpase inhibitors and antagonists thereof |
DE102005005397B4 (de) * | 2005-02-05 | 2008-08-21 | Lts Lohmann Therapie-Systeme Ag | Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms |
US20080194527A1 (en) * | 2007-02-14 | 2008-08-14 | Tcp Innovations Ltd | Compositions and combinations 2 |
US20110136858A1 (en) * | 2009-12-04 | 2011-06-09 | Grainger David J | Preferred Combination Therapy |
US8501690B2 (en) | 2010-04-30 | 2013-08-06 | John G. Stark | Use of selective estrogen receptor modulator for joint fusion and other repair or healing of connective tissue |
MY175800A (en) * | 2011-11-30 | 2020-07-09 | Astrazeneca Ab | Combination treatment of cancer |
AU2013205648B2 (en) * | 2011-11-30 | 2015-02-05 | Astrazeneca Ab | Combination treatment |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001089515A1 (en) * | 2000-05-23 | 2001-11-29 | Astrazeneca Ab | Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect |
WO2002002099A1 (en) * | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition |
JP2002513755A (ja) * | 1998-05-07 | 2002-05-14 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション | 前立腺癌の化学防御方法 |
WO2002089801A1 (en) * | 2001-05-10 | 2002-11-14 | Cedars Sinai Medical Center | Use of benzothiophenes to treat and prevent prostave cancer |
JP2003513903A (ja) * | 1999-11-08 | 2003-04-15 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション | 前立腺癌の予防的化学療法 |
WO2003043606A1 (en) * | 2001-11-16 | 2003-05-30 | Astrazeneca Uk Limited | Pharmaceutical formulation comprising bicalutamide |
WO2003047504A2 (en) * | 2001-11-29 | 2003-06-12 | Gtx Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US114519A (en) * | 1871-05-09 | Improvement in clothes-driers | ||
US25051A (en) * | 1859-08-09 | Nail-plate feeder | ||
US134899A (en) * | 1873-01-14 | Improvement in machines for making boot and shoe heels | ||
US36956A (en) * | 1862-11-18 | Improvement in the process of stripping tobacco-leaves | ||
US173445A (en) * | 1876-02-15 | Improvement in furnaces for brick-kilns | ||
US76695A (en) * | 1868-04-14 | Improved buttoi-eole lining foe caeeiage-cuetains | ||
US103141A (en) * | 1870-05-17 | Richard t | ||
BE637389A (ja) * | 1962-09-13 | |||
US3995060A (en) * | 1972-06-20 | 1976-11-30 | Schering Corporation | Antiandrogenic agents and method for the treatment of androgen dependent disease states |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
US4474813A (en) * | 1980-10-24 | 1984-10-02 | Schering Corporation | Pharmaceutical preparations comprising flutamide |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4420483A (en) * | 1982-07-22 | 1983-12-13 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same |
ATE28864T1 (de) * | 1982-07-23 | 1987-08-15 | Ici Plc | Amide-derivate. |
US5023088A (en) * | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
US5595985A (en) * | 1989-03-10 | 1997-01-21 | Endorecherche Inc. | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia |
US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
HUT60139A (en) * | 1989-07-07 | 1992-08-28 | Endorecherche Inc | Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen |
JP3157882B2 (ja) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
EP0748220A4 (en) | 1994-01-21 | 1997-09-10 | Sepracor Inc | METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX |
US6468981B1 (en) * | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
US6413534B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
EP1102755B1 (en) | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
US20020103141A1 (en) | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
WO2000074684A1 (en) * | 1999-06-04 | 2000-12-14 | The General Hospital Corporation | Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use |
US20030114519A1 (en) | 2000-05-23 | 2003-06-19 | Barrington Furr | Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition |
AU2001288213B2 (en) | 2000-06-28 | 2005-04-14 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
-
2004
- 2004-01-09 US US10/754,308 patent/US7332525B2/en not_active Expired - Fee Related
- 2004-01-12 AU AU2004207442A patent/AU2004207442B2/en not_active Ceased
- 2004-01-12 EP EP04701509A patent/EP1583536B1/en not_active Expired - Lifetime
- 2004-01-12 WO PCT/US2004/000668 patent/WO2004066962A2/en active Application Filing
- 2004-01-12 MX MXPA05007583A patent/MXPA05007583A/es active IP Right Grant
- 2004-01-12 CA CA2509390A patent/CA2509390C/en not_active Expired - Fee Related
- 2004-01-12 KR KR1020057013114A patent/KR20050096135A/ko not_active Application Discontinuation
- 2004-01-12 JP JP2006536528A patent/JP2007508397A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002513755A (ja) * | 1998-05-07 | 2002-05-14 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション | 前立腺癌の化学防御方法 |
JP2003513903A (ja) * | 1999-11-08 | 2003-04-15 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレーション | 前立腺癌の予防的化学療法 |
WO2001089515A1 (en) * | 2000-05-23 | 2001-11-29 | Astrazeneca Ab | Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect |
WO2002002099A1 (en) * | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition |
WO2002089801A1 (en) * | 2001-05-10 | 2002-11-14 | Cedars Sinai Medical Center | Use of benzothiophenes to treat and prevent prostave cancer |
WO2003043606A1 (en) * | 2001-11-16 | 2003-05-30 | Astrazeneca Uk Limited | Pharmaceutical formulation comprising bicalutamide |
WO2003047504A2 (en) * | 2001-11-29 | 2003-06-12 | Gtx Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
Also Published As
Publication number | Publication date |
---|---|
MXPA05007583A (es) | 2005-09-21 |
WO2004066962A3 (en) | 2004-12-02 |
AU2004207442A1 (en) | 2004-08-12 |
US20040142973A1 (en) | 2004-07-22 |
CA2509390C (en) | 2011-07-19 |
EP1583536B1 (en) | 2013-03-20 |
AU2004207442B2 (en) | 2008-06-19 |
US7332525B2 (en) | 2008-02-19 |
WO2004066962A2 (en) | 2004-08-12 |
EP1583536A2 (en) | 2005-10-12 |
KR20050096135A (ko) | 2005-10-05 |
EP1583536A4 (en) | 2009-07-15 |
CA2509390A1 (en) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007508397A (ja) | 前立腺癌の治療方法およびその治療組成物 | |
US9326974B2 (en) | Methods and related compositions for the treatment of cancer | |
RU2150275C1 (ru) | Применение 2-фенил-3-ароилбензотиофенов для снижения уровня холестерина в сыворотке,фармацевтическая композиция | |
US7098198B2 (en) | Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors | |
US20080113973A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2 | |
JP2008538784A (ja) | 膀胱機能を調節するための方法 | |
PT925069E (pt) | Utilização de cetrorelix para o tratamento da hipertrofia benigna da próstata e cancro da próstata | |
JP2022121599A (ja) | 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物 | |
JP2003531171A (ja) | 高脂血症関連疾患に対する組成物および治療 | |
ES2363914T3 (es) | Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante. | |
CZ288547B6 (cs) | Léčivo k modulaci kalciových kanálů ve vaskulární a kardiální tkáni | |
MXPA05008589A (es) | Metodo para el tratamiento de cancer de prostata y composicion para dicho tratamiento. | |
JP2004501967A (ja) | 抗アンドロゲン作用およびアロマターゼ阻害を与えるための抗アンドロゲンおよびタモキシフェンの医薬組合せ | |
EA014309B1 (ru) | Лечения приступообразных ощущений жара, индуцированных андрогенной депривацией | |
BE1009060A3 (fr) | Compositions pharmaceutiques et procede permettant leur preparation. | |
JP2008156239A (ja) | Sermを用いて脂質状態を改善する方法 | |
ES2699298T3 (es) | Método de tratamiento de la disfunción termorreguladora con paroxetina | |
CA2370501C (en) | Pharmaceutical composition for the therapy of lower urinary tract symptoms | |
WO2001034199A2 (en) | Oncolytic combinations for the treatment of cancer | |
WO2001021167A1 (en) | Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein | |
US20020198235A1 (en) | Use of benzothiopenes to treat and prevent prostate cancer | |
CN1738622A (zh) | 前列腺癌的治疗方法和治疗组合物 | |
KR20240027623A (ko) | 여성형 유방 및/또는 유방통 치료 | |
US20050059741A1 (en) | Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-1 | |
KR20010099647A (ko) | 신규 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101102 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110131 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111018 |